相似文献
1
Reply to "Comment on Casiraghi et al. 'Mucoadhesive Budesonide Formulation for the Treatment of Eosinophilic Esophagitis' 2020, , 211".
Pharmaceutics. 2020 Aug 28;12(9):822. doi: 10.3390/pharmaceutics12090822.
2
Comment on Casiraghi et al. "Mucoadhesive Budesonide Formulation for the Treatment of Eosinophilic Esophagitis" 2020, , 211.
Pharmaceutics. 2020 Aug 31;12(9):829. doi: 10.3390/pharmaceutics12090829.
3
Mucoadhesive Budesonide Solution for the Treatment of Pediatric Eosinophilic Esophagitis.
Pharmaceuticals (Basel). 2024 Apr 24;17(5):550. doi: 10.3390/ph17050550.
4
Mucoadhesive Budesonide Formulation for the Treatment of Eosinophilic Esophagitis.
Pharmaceutics. 2020 Mar 1;12(3):211. doi: 10.3390/pharmaceutics12030211.
5
Eosinophilic esophagitis: treatment with oral viscous budesonide.
Int J Pharm Compd. 2012 Jul-Aug;16(4):288-93.
6
Physical and Chemical Stability of Budesonide Mucoadhesive Oral Suspensions (MucoLox).
Int J Pharm Compd. 2017 Jul-Aug;21(4):322-329.
7
Thiolated hydroxypropyl-β-cyclodextrin as mucoadhesive excipient for oral delivery of budesonide in liquid paediatric formulation.
Int J Pharm. 2019 Dec 15;572:118820. doi: 10.1016/j.ijpharm.2019.118820. Epub 2019 Nov 7.
8
Active eosinophilic esophagitis is associated with impaired elimination of budesonide by cytochrome P450 3A enzymes.
Digestion. 2013;87(2):110-7. doi: 10.1159/000346403. Epub 2013 Jan 25.
9
Treatment of eosinophilic esophagitis with inhaled budesonide in a 7-year-old boy with concomitant persistent asthma: resolution of esophageal submucosal fibrosis and eosinophilic infiltration.
Ann Allergy Asthma Immunol. 2007 Dec;99(6):572-4. doi: 10.1016/S1081-1206(10)60390-0.
10
Budesonide Oral Suspension Improves Symptomatic, Endoscopic, and Histologic Parameters Compared With Placebo in Patients With Eosinophilic Esophagitis.
Gastroenterology. 2017 Mar;152(4):776-786.e5. doi: 10.1053/j.gastro.2016.11.021. Epub 2016 Nov 23.
引用本文的文献
1
The Design of Novel 3D-Printed, Moulded, and Oral Viscous Budesonide Formulations for Paediatrics: A Comparative Evaluation of Their Mucoadhesive Properties.
Pharmaceutics. 2024 Oct 18;16(10):1338. doi: 10.3390/pharmaceutics16101338.
2
Mucoadhesive Budesonide Solution for the Treatment of Pediatric Eosinophilic Esophagitis.
Pharmaceuticals (Basel). 2024 Apr 24;17(5):550. doi: 10.3390/ph17050550.
3
Rheological and Injectability Evaluation of Sterilized Poloxamer-407-Based Hydrogels Containing Docetaxel-Loaded Lipid Nanoparticles.
Gels. 2024 May 1;10(5):307. doi: 10.3390/gels10050307.
4
Utilizing 4D Printing to Design Smart Gastroretentive, Esophageal, and Intravesical Drug Delivery Systems.
Adv Healthc Mater. 2023 Apr;12(10):e2202631. doi: 10.1002/adhm.202202631. Epub 2023 Jan 18.
5
Formulations of Topical Steroids in Eosinophilic Esophagitis-Current Treatment and Emerging Possibilities.
J Clin Med. 2022 Mar 7;11(5):1454. doi: 10.3390/jcm11051454.
6
Critical Aspects in the Preparation of Extemporaneous Flecainide Acetate Oral Solution for Paediatrics.
Pharmaceutics. 2021 Nov 19;13(11):1963. doi: 10.3390/pharmaceutics13111963.
7
Comment on Casiraghi et al. "Mucoadhesive Budesonide Formulation for the Treatment of Eosinophilic Esophagitis" 2020, , 211.
Pharmaceutics. 2020 Aug 31;12(9):829. doi: 10.3390/pharmaceutics12090829.
8
Semisolid Dosage.
Pharmaceutics. 2020 Apr 1;12(4):315. doi: 10.3390/pharmaceutics12040315.
本文引用的文献
1
A Randomized Controlled Comparison of Esophageal Clearance Times of Oral Budesonide Preparations.
Dig Dis Sci. 2016 Jun;61(6):1582-90. doi: 10.1007/s10620-015-3990-4. Epub 2016 Feb 26.
2
Eosinophilic esophagitis: treatment with oral viscous budesonide.
Int J Pharm Compd. 2012 Jul-Aug;16(4):288-93.
Zotero 插件